BMJ14h
POS1428 IDENTIFICATION OF A WARM AUTOIMMUNE HEMOLYTIC ANEMIA (wAIHA) POPULATION USING PREDICTIVE ANALYTICS OF A KNOWN CLINICALLY PROFILED COHORT
1 Taussig Cancer Institute, Cleveland Clinic, Hematology and Medical Oncology, Cleveland, OH, United States of America 2 Clinical Communications and Patient Advocacy, Editas Medicine, Medical Affairs, ...
BMJ23h
POS1019 DIPYRIDAMOLE, A COMPOUND THAT INCREASES EXTRACELLULAR ADENOSINE LEVELS, AS A THERAPEUTIC AGENT FOR RHEUMATOID SARCOPENIA
Background In addition to joint damage, rheumatoid arthritis (RA) confers a higher risk of several comorbidities, including changes in body composition with reduced muscle mass and strenght ...
BMJ1d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ3d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ4d
Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis
Correspondence to Professor Annette van der Helm-van Mil, Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; A.H.M.van_der_Helm{at}lumc.nl Rheumatoid arthritis (RA) is ...
BMJ4d
Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo
Objectives Antitumour necrosis factor (TNF) therapy has revolutionised treatment of several chronic inflammatory diseases, including spondyloarthritis (SpA). However, TNF inhibitors (TNFi) are not ...
BMJ6d
Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs
Correspondence to Dr Jörg H W Distler, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, ...
BMJ6d
Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses
Objective Immune complexes (ICs) play a critical role in the pathology of autoimmune diseases. The aim of this study was to generate and characterise a first-in-class anti-FcγRIIA antibody (Ab) ...
BMJ11d
Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
Objectives To determine if disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) affect response to therapy in patients with established rheumatoid arthritis (RA).
BMJ12d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ14d
Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk
Objective We aimed to identify specific genetic-respiratory disease endotypes for rheumatoid arthritis (RA) risk. Methods This case–control study used the Mass General Brigham (MGB) and Mayo Clinic ...
BMJ16d
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study
Objective To compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK). Methods Fifty-three patients with active disease from an ongoing ...